Redeye endorses the FDA’s decision to characterize BONESUPPORT’s CERAMENT G as a Breakthrough Device for the trauma indication. We raise our Base Case somewhat on the back of the assumption that this designation helps enable speedy cost coverage, potential NTAP, and overall (slight) increased market adoption. It also reduces the regulatory delay risk.
LÄS MER
